1-3 of 3
Peter Dove
Close
Sort by
Journal Articles

TTI-281, an Orally Bioavailable Bromodomain and Extraterminal Domain (BET) Inhibitor, Is a Promising Candidate for the Treatment of Multiple Myeloma

Zezhou Wang, PhD, Jaehyun Choi, PhD, Peter Dove, Chunlei Wang, Aaron D. Schimmer, MD PhD, Penka S. Petrova, PhD, Robert A. Uger, PhD, Malik Slassi, PhD
Journal: Blood
Blood (2016) 128 (22): 2095.
https://doi.org/10.1182/blood.V128.22.2095.2095
Published: 2016
Journal Articles

The Highly Potent Bromodomain (BRD) Inhibitor FV-281 Displays Preclinical Efficacy in Acute Myeloid Leukemia (AML)

Zezhou Wang, PhD, Peter Dove, Aisha Shamas-Din, PhD, Rose Hurren, Xiaoming Wang, Neil MacLean, Marcela Gronda, Feng Bo, Janessa Li, Clarissa Skorupski, Wissam Hadri, David O'Neill, PhD, Ahmed Aman, PhD, Rima Al-awar, PhD, Mark D. Minden, MD PhD, Malik Slassi, PhD, Aaron D. Schimmer, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1364.
https://doi.org/10.1182/blood.V126.23.1364.1364
Published: 2015
Journal Articles

FV-162 Is a Novel Orally Bioavailable Proteasome Inhibitor With Improved Pharmacokinetics That Displays Preclinical Efficacy In Vitro and In Vivo

Zezhou Wang, PhD, Peter Dove, Xiaoming Wang, Carolyn A. Goard, PhD, Zhihua Li, Alex Nachman, Yoonsun Jenny Oh, Rose Hurren, Amy Ruschak, PhD, Shane Climie, PhD, David O'Neill, PhD, Barry Press, PhD, Carly Griffin, PhD, Elijus Undzys, Ahmed Aman, PhD, Rima Al-awar, PhD, Lewis Kay, PhD, Suzanne Trudel, MD, MSC, FRCPC, Malik Slassi, PhD, Aaron Schimmer, PhD, MD
Journal: Blood
Blood (2013) 122 (21): 1988.
https://doi.org/10.1182/blood.V122.21.1988.1988
Published: 2013